ArticleBiophysical journal2001
T-cell activation by soluble MHC oligomers can be described by a two-parameter binding model.
Article in Biophysical journal, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 49 citations in OpenAlex.
- T Cell Assay to Track Presentation of an Influenza Hemagglutinin Epitope Presented by the MHC-II Protein HLA-DR1.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Design of Crosslinking Antibodies For T-Cell Activation: Experimental and Computational Analysis of PD-1/CD137 Bispecific Agents.The AAPS journal · 2024Article
- The Role and Therapeutic Implications of Inflammation in the Pathogenesis of Brain Arteriovenous Malformations.Biomedicines · 2023Review
- Multivalent, asymmetric IL-2-Fc fusions show enhanced selectivity for regulatory T cells.Science signaling · 2023Article
- Mixed IgG Fc immune complexes exhibit blended binding profiles and refine FcR affinity estimates.Cell reports · 2023Article
- Mixed IgG Fc immune complexes exhibit blended binding profiles and refine FcR affinity estimates.bioRxiv : the preprint server for biology · 2023Article
- A quantitative view of strategies to engineer cell-selective ligand binding.Integrative biology : quantitative biosciences from nano to macro · 2021Article
- A general model of multivalent binding with ligands of heterotypic subunits and multiple surface receptors.Mathematical biosciences · 2021Article
- Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies.Journal for immunotherapy of cancer · 2021Article
- Relationship of 2D Affinity to T Cell Functional Outcomes.International journal of molecular sciences · 2020Review
- Optogenetic control shows that kinetic proofreading regulates the activity of the T cell receptor.eLife · 2019Article
- A humanized TCR retaining authentic specificity and affinity conferred potent anti-tumour cytotoxicity.Immunology · 2018Article
- Dissecting FcγR Regulation through a Multivalent Binding Model.Cell systems · 2018Article
- Linking form to function: Biophysical aspects of artificial antigen presenting cell design.Biochimica et biophysica acta · 2015Review
- Titrating T-cell epitopes within self-assembled vaccines optimizes CD4+ helper T cell and antibody outputs.Advanced healthcare materials · 2014Article
- Receptor Pre-Clustering and T cell Responses: Insights into Molecular Mechanisms.Frontiers in immunology · 2014Review
- T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- A stochastic T cell response criterion.Journal of the Royal Society, Interface · 2012Article
- Bifunctional Janus microparticles with spatially segregated proteins.Langmuir : the ACS journal of surfaces and colloids · 2012Article
- Supramolecular complexing of membane Siglec CD22 mediated by a polyvalent heterobifunctional ligand that templates on IgM.Bioconjugate chemistry · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
T-cell activation is essential for initiation and control of immune system function. T cells are activated by interaction of cell-surface antigen receptors with major histocompatibility complex (MHC) proteins on the surface of other cells. Studies using soluble oligomers of MHC-peptide complexes and other types of receptor cross-linking agents have supported an activation mechanism that involves T cell receptor clustering. Receptor clustering induced by incubation of T cells with MHC-peptide oligomers leads to the induction of T-cell activation processes, including downregulation of engaged receptors and upregulation of the cell-surface proteins CD69 and CD25. Dose-response curves for these T-cell activation markers are bell-shaped, with different maxima and midpoints, depending on the valency of the soluble oligomer used. In this study, we have analyzed the activation behavior using a mathematical model that describes the binding of multivalent ligands to cell-surface receptors. We show that a simple equilibrium binding model accurately describes the activation data for CD4(+) T cells treated with MHC-peptide oligomers of varying valency. The model can be used to predict activation and binding behavior for T cells and MHC oligomers with different properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.